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Objectives—Fibrin makes up the structural basis of an occlusive arterial thrombus, and variability in fibrin phenotype
relates to cardiovascular risk. The aims of the current study from the EU consortium EuroCLOT were to (1) determine
the heritability of fibrin phenotypes and (2) identify QTLs associated with fibrin phenotypes.
Methods and Results—447 dizygotic (DZ) and 460 monozygotic (MZ) pairs of healthy UK white female twins and 199
DZ twin pairs from Denmark were studied. D-dimer, an indicator of fibrin turnover, was measured by ELISA and
measures of clot formation, morphology, and lysis were determined by turbidimetric assays. Heritability estimates and
genome-wide linkage analysis were performed. Estimates of heritability for d-dimer and turbidometric variables were
in the range 17% to 46%, with highest levels for maximal absorbance which provides an estimate of clot density.
Genome-wide linkage analysis revealed 6 significant regions with LOD 3 on 5 chromosomes (5, 6, 9, 16, and 17).
Conclusions—The results indicate a significant genetic contribution to variability in fibrin phenotypes and highlight
regions in the human genome which warrant further investigation in relation to ischemic cardiovascular disorders and
their therapy. (Arterioscler Thromb Vasc Biol. 2009;29:600-605.)
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The EuroCLOT consortium is an EU-funded multi-centercollaborative study established to identify QTLs associ-
ated with fibrin clot phenotypes to shed light on the patho-
genic mechanisms of ischemic cardiovascular disease (stroke
and myocardial infarction). In both myocardial infarction and
ischemic stroke, acute thrombosis is the key final step leading
to tissue damage in the territory served by the vessel.
Increased levels of hemostatic factors, including fibrinogen1
and tissue plasminogen activator (tPA),2 predict development
of cardiovascular disorders and outcome.
Activation of the coagulation cascade results in thrombin
generation and cleavage of fibrinogen to form fibrin mono-
mers, which polymerize and are cross-linked by thrombin-ac-
tivated factor XIII, to form the structural scaffold for throm-
bus formation. Fibrinolysis of fibrin clots is influenced by
various factors including the fibrin binding characteristics of
tPA/plasminogen, local concentrations of fibrinolysis inhibi-
tors, and the structure of the clot. For example, studies in vitro
have shown that dense clots composed of thinner fibers lyse
more slowly than less dense clots formed from thicker
fibers.3,4 Alterations in clot structure/function, including in-
creased clot density and decreased clot lysis times, have been
observed in subjects with arterial and venous thrombosis,5,6
although the association with clinical outcome in healthy
volunteers is unclear at present. We have recently shown that
genetic factors contribute to variance in turbidimetric mea-
sures of clot structure/function,7 and numerous studies have
demonstrated genetic influences on proteins involved in
coagulation and fibrinolysis. Furthermore, genetic factors
have been estimated to account for approximately 60% of the
risk of thrombosis.8 Consequently, the identification of ge-
netic loci influencing clot structure/function may further our
understanding of the underlying factors predisposing to oc-
clusive vascular diseases.
The aims of the current study from EuroCLOT were to (1)
determine the heritability of fibrin phenotypes and (2) iden-
tify QTLs associated with fibrin phenotypes in healthy twin
volunteers from the UK and Denmark.
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Materials and Methods
Subject Recruitment and Sample Handling
The Twins UK Adult Twin Registry9 and the Danish Twin Registries
study on endophenotypes10 provided the subjects for this study
(please see supplemental materials, available online at http://atvb.
ahajournals.org.). Venous blood was drawn at the participating
centers following a standard protocol for venepuncture and sample
processing for citrated plasma as previously reported.11 EDTA-
anticoagulated whole blood samples were also obtained for DNA
extraction. Citrated plasma aliquots, for analysis of D-dimer and
turbidimetric fibrin phenotypes, were snap frozen in liquid nitrogen
then stored at 80°C. Samples were batched up and transported on
dry ice to the University of Leeds for phenotyping (see below).
Genotyping for linkage analysis was performed by Gemini-
Sequenom, Cambridge (UK samples) and by Genotyping Centre
Helsinki, as part of GenomEUtwin (Denmark samples).12 Genotyp-
ing and phenotyping raw data were sent to King’s College London
for collation and analysis.
Laboratory Methods
Fibrin Phenotypes
D-dimer levels were determined according to the manufacturers’
instructions using TintElize(r) D-dimer ELISA kit, (Biopool, Umea,
Sweden). Inter- and intraassay CVs were 5.6 and 3.3%, respectively.
The high throughput turbidimetric assay of clot structure using
customized software was performed as described elsewhere.7 The
following variables were analyzed: LagC, (which represents the time
at which sufficient protofibrils have formed to enable lateral aggre-
gation, was taken as the time point at which an exponential increase
in absorbance occurred), MaxAbsC (a measure of clot density
reflected by the absorbance at which 3 consecutive readings were
identical corrected for the LagC absorbance), Lys50t0 (calculated as
the time from initiation of clot formation to the time at which a 50%
fall in absorbance from MaxAbsL occurred), and AUC (area under
the curve, reflecting the balance between coagulation and fibrinoly-
sis) The interassay CVs for LagC, MaxAbsC, Lys50t0, and AUC were
8%, 4%, 7.0%, and 16%, respectively.
Genotyping
Standard methods were used for linkage genotyping (see
supplemental materials).
Statistical Analysis
Heritability Estimates
For each phenotype (D-dimer, LagC, MaxAbsC, Lys50t0, and AUC)
data were transformed using a Box-Cox transformation to make their
distributions approximately normal. Observations that were more
than 3 standard deviations away from the mean were considered
outliers and excluded from the analyses.13 Modeling for heritability
assumes phenotypic variance to be attributable to three latent factors,
namely additive polygenic effects (A), common environment (C),
and specific individual effects and measurement error (E). Please see
supplemental materials.
Linkage Analysis
Genotype and phenotype data were available on 447 UK DZ pairs
and 199 DZ Danish pairs. Phenotype data (D-dimer, LagC, Max-
AbsC, Lys50t0, and AUC) were analyzed using R.13 Data were
transformed to optimize closeness to normality using a Box-Cox
transformation using the box.cox.power function in the car pack-
age,14,15 to reduce the type I errors while preserving power for
phenotypes having skewed distribution.16 For details of joint linkage
analysis please see supplemental materials.
Results
Initially 2422 UK and 429 Danish twins were recruited to the
study. After genotyping and phenotyping and the removal of
outliers as described above, complete data were available on
1814 UK female twins (447 DZ pairs and 460 MZ pairs) and
199 unselected Danish DZ twin pairs (Table 1).
Heritability Estimates
Narrow sense heritability (proportion of phenotypic variance
attributable to additive genetic factors) requires data from
both MZ and DZ twins, so the UK twin sample was used.
Examination of the ACE model and its submodels revealed,
in each phenotype, that the ACE model provided the best
explanation of the observed data (data not shown). Heritabil-
ity estimates obtained from the ACE model were in the range
17% to 46% (Table 2). These results indicate a significant
contribution of additive genetic factors to variance in fibrin
clot structure and function as measured by the 5 phenotypes
(Table 2, column A).
Linkage Analysis
Genome-wide linkage analysis using the combined datasets
identified evidence of linkage at a number of regions (Table
3). Regions with LOD 3 included Lagc on chromosome
6p22.2-q16.1 with peak LOD score 3.6 (Figure, panel B) at
marker D6S426; on chromosome 9q22.1-q22.33 with maxi-
mum LOD3.53 at marker D9S287 (Figure, panel C);
chromosome 16p13.2-p13.13 with peak LOD score 4.57
(Figure, panel D) at marker D16S404. The first of these
peaks, on chromosome 6, also showed linkage for Lys50t0
with a partially overlapping peak with LOD 4.2 at marker
Table 1. Characteristics of UK and Danish Twins and Their
Phenotypes
Population UK Twins Denmark Twins
Sample size 1814 398
% females 100 50.3
No MZ pairs 447 0
No DZ pairs 460 199
Age/mean (range), y 57 (48–64) 36 (29–49)
Ddimer/median (IQ range), ng/ml 77 (56–112) 64 (48–87)
Lys50t0/median (IQ range) 1716 (1531–1975) 1377 (1270–1542)
AUC/median (IQ range) 366 (250–533) 302 (224–415)
Lagc/median (IQ range) 343 (297–394) 282 (250–321)
MaxAbsc/median (IQ range) 0.41 (0.35–0.47) 0.31 (0.25–0.37)
MZ indicates monozygotic; DZ, dizygotic; y, years; IQ, interquartile.
Phenotypes are defined in the Methods.
Table 2. Estimates for Additive Genetics Effects (A), Common
Environment (C), and Specific Individual Effects and
Experimental Error (E) and 95% Confidence Intervals for UK
Twins
Phenotype A C E
D-dimer 25% (6%–44%) 18% (3%–33%) 57% (50%–64%)
Lys50t0 23% (11%–35%) 47% (37%–55%) 30% (27%–35%)
AUC 28% (15%–40%) 41% (30%–51%) 31% (28%–37%)
Lagc 17% (8%–25%) 62% (55%–69%) 21% (18%–25%)
MaxAbsc 46% (30%–62%) 15% (2%–28%) 39% (34%–45%)
Estimates shown are derived from the ACE model which was found to be the
best fitting model for each phenotype.
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D6S462 (Figure, panel B). Evidence of linkage was also
observed for AUC on chromosome 17q22-q24.3 with peak
LOD score 3.51 (Figure) at marker D17S944 and for d-dimer
on chromosome 5q14.1-q21.3 with LOD3.51. Suggestive
linkage17 was observed for Lagc on chromosomes 1, 3, and
17; for Lys50t0 on chromosomes 4, 5, 6, 9, 12, and 17; and for
D-dimer on chromosome 14 (Table 3).
Discussion
Over the last 20 years there has been considerable progress in
understanding the contribution of abnormalities in hemostasis
to the pathogenesis of vascular disease. Alterations in indi-
vidual components of the coagulation and fibrinolytic path-
ways have been related to both cardio- and cerebrovascular
disease in case control and prospective studies.1,2,18 Evidence
indicates genetic contributions to most aspects of these
pathways,19,20 including a substantial genetic component to
the structure and function of fibrin.21,22 Taken together, these
observations support the view that genetic factors contribute
ultimately to vascular risk.
The heritability study shows varying degrees of genetic
influence on fibrin phenotypes, with the strongest effect on
MaxAbsc, a measure of clot density, at 46%. The heritabilities
obtained are similar to those we have previously described in
twin21 and family7 studies. These results confirm that the
intermediate fibrin-related phenotypes are heritable and that a
genome-wide approach offers a tractable strategy for the
elucidation of underlying genetic factors. Multipoint linkage
analysis of fibrin phenotypes revealed 6 chromosomal re-
gions with significant linkage peaks (LOD scores 3.0) and
a further 9 regions of suggestive linkage (LOD scores 2.0 to
3.0). The peaks having significant linkage did not harbor any
obvious known structural genes for coagulation or fibrino-
lytic factors that might influence fibrin phenotypes.
The development of occlusive thrombotic disease is depen-
dent on the formation of a cross-linked fibrin mesh which in
the arterial system supports incorporation of platelets and
platelet particles. The mechanisms involved in regulation of
fibrin structure/function are complex and involve coagulation
and fibrinolytic proteins, other plasma components, and
regulatory factors. Fibrin formation itself occurs after activa-
tion of the coagulation system with consequent thrombin
generation, fibrinogen cleavage, and activation of coagulation
FXIII, all of which contribute to the final fibrin phenotype.
That fibrin formed from plasma ex vivo differs markedly
from that formed by recombinant or purified fibrinogen23
suggests that additional plasma components contribute to the
clot phenotype—mediated, perhaps, by diverse mechanisms.
Preliminary data from the fibrin proteome indicate a range of
immunoglobulins, inflammatory proteins, and other plasma
components associates with the fibrin matrix and could alter
structure/function.24,25 Finally, regulatory factors influencing
gene transcription, posttranslational modification, and protein
degradation modify all processes leading to fibrin clot for-
mation. For example, PAI-1 levels are related to a PAI-1 gene
promoter polymorphism,26 modulated by triglyceride levels27
and regulated by the transcriptional factor PPAR28,29 and
components of the molecular clock.30 Similarly, there are
substantial data indicating that fibrinogen is regulated by
complex genetic influences.22
The above should be borne in mind when interpreting the
results. Although several highly significant linkage peaks
were identified, there was little to suggest the peaks covered
structural genes coding for coagulation or fibrinolytic pro-
teins. There was, however, a suggestive linkage peak for
Lys50t0 (6q26-q-ter) in proximity to genes encoding plasmin-
ogen and lipoprotein(a), which have clearly defined roles in
fibrinolysis.31
A variety of potentially important regulatory genes were
identified. For the wide AUC 17q22-q24.3 peak a number of
putative candidates were identified, including HLF (hepatic
leukemia factor) and GNA13 (guanine nucleotide binding
protein -13). HLF transactivates the genes encoding coag-
ulation factors FVIII and FIX,32 and GNA13 is involved in
platelet signaling and deficiency in mice leads to decreased
response to thrombin, thromboxane A2, and collagen and
decreased thrombus formation under flow.33 Furthermore,
this region has been linked to clustering of metabolic syn-
drome components.34 In addition, the 14q24.1-q32.13
D-dimer peak harbors a SERPIN cluster which includes
SERPINA10 which inhibits Factors Xa and XIa and has been
associated with thrombosis in a mouse model.35 The 3p26.3-
p25.3 peak for LagC contains SNPs associated with FVII and
fibrinogen in the Framingham Heart Study.36
For several other linkage peaks putative candidate genes
for thrombosis or cardiovascular disease were identified. The
highest LOD scores were observed for Lagc and AUC (4.57
and 3.51) on chromosomes 16 and 17, respectively. The
16p13.2-p13.13 peak (Lagc) has been linked to type 1
diabetes (T1DM)37 and carotid artery calcified plaque in
T2DM.38 The 1p13.2-q21.3 peak includes 2 SNPs associated
with LDL.39 The 12q24.32-q-ter (Lys50t0) peak corresponds
to a bivariate linkage locus for cholesterol and HDL40 and a
Table 3. Details of the Linkage Peaks Having LOD>2 for the
DZ Twins From UK and Denmark
Chromosome Trait Flanking Markers* Peak-LOD
1p13.2-1q21.3 Lagc WIAF_3798 - WIAF_3272 2.27
3p26.3-3p25.3 Lagc D3S4559 - D3S1263 2.17
4p16.1-4p15.1 Lys50t0 D4S2935 - WIAF_3923 2.01
5q14.1-q21.3 d-dimer WIAF_1721 - WIAF_3198 3.51
5q23.1-5q31.3 Lys50t0 WIAF_3210 - WIAF_2528 2.57
6p22.2-q16.1 Lagc D6S1691 - WIAF_577 3.60
6q14.1-16.1 Lys50t0 D6S460 - WIAF_577 4.20
6q26-q-ter Lys50t0 D6S1599 - q-ter 2.63
9q22.1-q22.33 Lagc WIAF_2079 - D9S1690 3.53
9p21.2-9p13.1 Lys50t0 D9S171 - WIAF_975 2.55
12q24.32-q-ter Lys50t0 D12S1679 - q-ter 2.45
14q24.1-14q32.13 D-dimer WIAF_2677 - WIAF_1602 2.62
15q13.3-q21.3 MaxAbsC WIAF_1283 - D15S117 2.18
16p13.2-p13.13 Lagc D16S423 - D16S3075 4.57
17p13.3-17p13.1 Lagc D17S831 - D17S945 2.76
17q22-q24.3 AUC D17S787 - D17S949 3.51
*1 cM confidence interval.
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locus for insulin resistance41 and contains a SNP associated
with vWF.36 The 6p22.2-q16.1 (LagC) peak is very wide and
partially overlaps with the 6q14.1-q16.1 Lys50t0 peak. The
former includes the lymphotoxin- (LTA) gene; LTA SNPs
have been associated with MI.42 This region also corresponds
to a QTL for LDL in a Samoan sample40 and 2 SNPs
associated with vWF in the Framingham Heart Study.36 Of
particular note, the 9p21.2-p13.1 Lys50t0 peak corresponds
with replicated loci for cardiovascular disease43 and T2DM.44
Together, these results suggest mechanisms for linking ge-
netic loci to cardiovascular risk through effects on fibrin
structure/function.
This study contained an excess of women, present for
historical reasons. There are significant gender differences in
vascular risk, mediated by hormonal influences and environ-
mental exposure, and it is possible that a study of men might
produce different results. Another potential limitation is that
the samples comprised twins. However, twins have been
shown to be comparable to singletons for many common
traits and diseases,45,46 and same sex dizygotic twin pairs
actually offer considerable advantages in linkage studies
because intrapair age and sex differences are eliminated and
the effect of the individual-specific random environment is
reduced.
Several steps need to be taken in EuroCLOT to link the
current findings to vascular outcomes. These include fine
mapping, prospective, and case–control studies of cardiovas-
cular disease and functional studies of the genes and their
encoded proteins. Ultimately, this work will further under-
standing of the mechanisms underlying the pathogenesis of
occlusive vascular disease and could potentially provide
novel therapeutic targets for the amelioration of the effects of
these common disorders.
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 Supplemental Material - Methods 
Subject recruitment and sample handling 
All the participating twins were self reported healthy volunteers. All participants gave written 
informed consent before entering the study and the St Thomas’ Hospital research ethics 
committee approved the UK part of the project, while all the Danish regional Scientific-
Ethical Committees approved the Danish part. DNA-based microsatellite markers with the 
PE Applied Biosystems AmpFISTR Profiler Plus Kit were used to determine zygosity of the 
Danish twins. 
 
Phenotyping 
In brief,  25μl of citrated plasma was added to 75μl assay buffer (0.05M Tris-HCl, 0.1M NaCl, 
pH 7.4), and 50μl of activation mix (final concentrations: 0.03 U/ml thrombin [Calbiochem], 
and 7.5 mmol/l calcium in assay buffer) was added to each column of the 96-well plate using 
a multichannel pipette at 10 sec intervals.  Plates were shaken and read at 340 nm every 12 
sec for 1h in a BIO-TEK ELx-808 microplate reader.  The turbidimetric lysis assay was 
carried out as above with the addition of 12.5 ng of tPA (Technoclone) to the 75μl assay 
buffer (83 ng/ml final concentration) prior to addition of activation mix. Plates were read at 
340 nm every 12 sec for 1h and subsequently every 2 min for up to 9h. 
 
Genotyping 
For the UK sample, genotyping was performed using 2231 polymorphic genetic markers - 
737 microsatellite markers from the ABI Prism set (Applied Biosystems, Foster City, CA) and 
1494 SNP markers from the HuSNP GeneChip linkage mapping set (Affymetrix Inc. Santa 
Clara, CA), as described previously1. The estimated genotyping error rate was < 1%.  Allele 
frequencies were estimated from the whole sample of genotyped subjects. The map 
positions were taken from Rutgers combined linkage physical map (MAP-O-MAT). The 
genetic locations of markers not on the Rutgers maps were interpolated from their physical 
position. The Danish twins were genotyped as part of the GenomEUtwin consortium as 
described by Perola et al2. 
Heritability 
Data were modelled using structural equation models implemented in Mx3 to obtain 
estimates for the parameters of the ACE model and its sub-models AE, CE and E.  The full 
model (ACE) was compared to submodels AE, CE and E to find the best fitting model with 
comparison of the fit made using a chi-square difference test. If this test statistic is not 
significant, the reduced model is accepted as the more parsimonious explanation of the 
data, otherwise the full model is retained. In all analyses, age was included as a covariate 
(Table 2). 
Joint Linkage Analysis 
To evaluate jointly the partially overlapping UK and DK linkage results, multipoint identity-by-
descent (IBD) probabilities were calculated on a 1 cM grid using Merlin4 for each sample 
separately, using their specific genetic map and allele frequencies. The IBD estimates were 
collected in a single IBD file and the two samples were pooled together in a joint linkage 
analysis using the variance component engine implemented in QTDT5.  Age, sex and 
country of origin were considered the most important vascular risk factors in this study so 
they were included as covariates in the linkage analysis. Approximate support intervals (SI) 
were generated using a -1 LOD approach. 
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